Cure SMA Celebrates FDA Approval of Itvisma™ for SMA Treatment
Cure SMA is excited about the recent approval of Itvisma™ (onasemnogene abeparvovec-brve) by the FDA. This advancement offers hope for adults and children aged two years and older living with spinal muscular atrophy (SMA).
Impacts of Itvisma™ on SMA Patients
The newly approved Itvisma™ is a revolutionary one-time gene therapy designed to deliver a functional SMN1 gene to motor neurons. This gene therapy is crucial as it helps restore the production of the SMN protein, which is vital for motor neuron function. Clinical studies demonstrate that Itvisma™ can enhance motor functions and provide prompt therapeutic advantages for older children and adults dealing with SMA.
Kenneth Hobby's Vision
President of Cure SMA, Kenneth Hobby, expressed, "This approval marks a monumental achievement for the SMA community. Families of older children have eagerly anticipated access to this innovative treatment method. Our commitment to supporting research and advocating for better treatment options has always focused on providing meaningful support for individuals who need it most."
Community Webinar and Support Initiatives
Cure SMA plans to hold a community webinar to discuss this important development on December 11. This initiative aims to provide essential resources, such as a treatment site locator tool and insurance guidance, to ensure families are well-informed about their options. In addition, the organization will highlight its advocacy efforts to promote treatment coverage.
Investment in SMA Research
According to Cure SMA, the accomplishments achieved today stem from decades of dedication and effort within the SMA community, involving individuals, families, healthcare professionals, and advocates. Over the last 30 years, more than $92 million has been channeled into SMA research, laying the groundwork for significant breakthroughs like Itvisma™.
Looking Ahead: Education and Advocacy
Jackie Glascock, the Chief Scientific Officer at Cure SMA, noted that while this approval is worth celebrating, the organization remains focused on supporting families in navigating this new therapy. "Equipping families with information and resources is crucial while we continue to advocate for fair access to this treatment," she mentioned.
The collaborative efforts between Cure SMA, Novartis, and other partners represent a commitment to broadening treatment options for individuals suffering from SMA. As the organization prepares to embark on its next phase of community support, it expresses profound gratitude towards the community members who have contributed to this significant achievement.
Understanding Spinal Muscular Atrophy (SMA)
Spinal muscular atrophy (SMA) is a progressive disease that deteriorates motor nerve cells in the spinal cord. This condition is responsible for affecting vital muscle functions necessary for activities such as breathing and walking. It’s essential to understand that SMA occurs in approximately 1 in every 15,000 live births in the U.S., with around 1 in 50 Americans being genetic carriers.
About Cure SMA
Cure SMA functions as the foremost nonprofit organization dedicated to the advocacy, support, and research pertaining to SMA. Its mission revolves around pushing forward research into potential treatments and eventual cures while empowering individuals affected by this condition.
Frequently Asked Questions
What is Itvisma™?
Itvisma™ is a one-time gene therapy approved by the FDA to treat spinal muscular atrophy (SMA) in individuals two years and older.
Who can benefit from Itvisma™?
Itvisma™ is beneficial for adults and children aged two or older who are living with all types of SMA.
What are the expected outcomes of Itvisma™ therapy?
The therapy aims to restore the production of the SMN protein, improving motor function and potentially halting or slowing the progression of SMA.
How does Cure SMA support the community?
Cure SMA offers educational resources, patient support, and advocacy initiatives to ensure access to treatments for those affected by SMA.
What is the mission of Cure SMA?
The mission of Cure SMA is to drive research for effective treatments and provide support for individuals impacted by spinal muscular atrophy.
